Skip to main content

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

Completed · Phase 3 · NCT04750226

Conditions: Parkinson's Disease (PD)

At a glance

Research payments reported, 2025
$488,890
U.S. investigators named
27
Sites paid
34
Planned or actual enrollment
118

About the trial

Sponsor
AbbVie
Tested
ABBV-951 (drug)
Dates
Started 2021-02-18; completion 2026-04-27
Results posted
Not yet

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how safe and effective ABBV-951 is in adult participants with PD. Adverse events and change in disease activity is evaluated. ABBV-951 is an investigational (unapproved) drug containing Levodopa Phosphate/Carbidopa Phosphate (LDP/CDP) given as an infusion under the skin for the treatment of Parkinson's Disease. Adult participants with advanced PD and who have completed M15-736 or M20-339 study will be enrolled. Approximately 130 p…

From ClinicalTrials.gov, last updated 2026-06-01. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $488,890 in research payments for this study in 2025 (106 payments).

Products named: Vyalev

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.